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http://dx.doi.org/10.1016/j.ccr.2013.05.005SUMMARYAmplification ofMYCN is a drivermutation in a subset of human neuroendocrine tumors, including neuroblas-
toma. No small molecules that target N-Myc, the protein encoded by MYCN, are clinically available. N-Myc
forms a complex with the Aurora-A kinase, which protects N-Myc from proteasomal degradation. Although
stabilization of N-Myc does not require the catalytic activity of Aurora-A, we show here that two Aurora-A in-
hibitors, MLN8054 and MLN8237, disrupt the Aurora-A/N-Myc complex and promote degradation of N-Myc
mediated by the Fbxw7 ubiquitin ligase. Disruption of the Aurora-A/N-Myc complex inhibits N-Myc-depen-
dent transcription, correlating with tumor regression and prolonged survival in a mouse model of MYCN-
driven neuroblastoma. We conclude that Aurora-A is an accessible target that makes destabilization of
N-Myc a viable therapeutic strategy.INTRODUCTION
Deregulated expression of MYC, MYCL, or MYCN, which
encode c-Myc, L-Myc, and N-Myc, respectively, contributes to
the genesis of multiple human tumors. Amplification of MYCN
is found in neuroendocrine tumors, including neuroblastoma,
small cell lung carcinoma, and neuroendocrine prostate cancer
(Beltran et al., 2011; Brodeur et al., 1984; Kim et al., 2006).
Deregulated expression of MYCN also occurs in tumors lacking
MYCN amplification, since MYCN is downstream of severalSignificance
Multiple previous studies suggest that targetingmembers of th
benefit in human tumors. Deregulated expression of N-Myc, o
diatric and adult neuroendocrine tumors. We show here that it
that disrupt the interaction betweenN-Myc and the Aurora-A ki
of neuroblastoma, such inhibitors induce differentiation and
benefit.oncogenic signal transduction pathways (Valentijn et al., 2012).
Paradigmatic examples are mutations in the sonic hedgehog
pathway that drive a subset of human medulloblastomas and
lead to constitutively elevated expression of MYCN (Hatton
et al., 2006; Kawauchi et al., 2012).
Similar to c-Myc, the N-Myc protein is a DNA binding helix-
loop-helix/leucine zipper protein that forms an obligate hetero-
dimer with a partner protein termed Max (Wenzel et al., 1991).
Both the interface between the two subunits and the interface
between the dimer and the DNA sequences it bound areeMyc family of oncoproteins will have significant therapeutic
ne of the three Myc family members, is prevalent in both pe-
is possible to target N-Myc indirectly using small molecules
nase, which is critical for stabilizing N-Myc. In amousemodel
senescence in tumors and achieve significant therapeutic
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Figure 1. Effect of MLN8054 on N-Myc Expression and Stability in MYCN-Amplified Neuroblastoma Cell Lines
(A) The panels show immunoblots of IMR-32 and IMR-5 cells treated for 48 hr with the indicated concentrations of MLN8054 or solvent control (0.1% v/v DMSO).
The results are representative of four independent experiments (n = 4; unless otherwise indicated, n indicates the number of independent experiments in the
following legends).
(B) The panels show representative immunoblots of five MYCN-amplified neuroblastoma cell lines upon treatment with MLN8054 (1,000 nM; 48 hr) or solvent
control (n = 3). Ratios of N-Myc to vinculin are indicated below the panel.
(C) The graphs show quantitative RT-PCR assays ofMYCNmRNA levels relative to b2-microglobulin and RPS14 as control. RNA was isolated from the indicated
cell lines treated with MLN8054 (1,000 nM, 24 hr) or solvent control. Error bars indicate mean +SD of triplicate technical assays (n = 2).
(legend continued on next page)
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Aurora-A Inhibitors Target N-Mycextensive, and currently no small molecule inhibitors that tar-
get the heterodimeric complex are clinically available. Since
N-Myc binds to a large set of target genes, defining critical onco-
genic effector pathways that can be targeted for therapeutic
intervention is also difficult (Chen et al., 2008).
Like c-Myc, N-Myc is degraded via the ubiquitin-proteasome
system. One ubiquitin ligase that targets N-Myc for proteasomal
degradation is Fbxw7, which recognizes N-Myc upon phosphor-
ylation at both S62 and T58 (Sjostrom et al., 2005). The mitotic
kinase cyclin B/CDK1 phosphorylates S62, thereby priming
phosphorylation at T58 by GSK3b. As a result, N-Myc is specif-
ically degraded duringmitosis (Sjostrom et al., 2005). This mech-
anism is thought to enable cell-cycle exit and differentiation of
neural progenitor cells and to ‘‘reset’’ N-Myc levels before the
start of the next cell cycle.
MYCN-amplified neuroblastoma cells express elevated levels
of Aurora-A, a kinase that is expressed and active during G2 and
mitosis (Marumoto et al., 2005; Otto et al., 2009). Aurora-A asso-
ciates with N-Myc and prevents Fbxw7-mediated proteasomal
degradation of N-Myc. MYCN-amplified neuroblastoma cells
depend on high levels of Aurora-A expression for maintaining
N-Myc function (Otto et al., 2009). Similarly, Aurora-A and
N-Myc bind each other and together drive an oncogenic gene
expression program in neuroendocrine prostate tumors (Beltran
et al., 2011). Neither complex formation with nor stabilization of
N-Myc requires the catalytic activity of Aurora-A. As a result,
several Aurora kinase inhibitors have no discernible effect on
N-Myc turnover (Otto et al., 2009). However, complex formation
requires the kinase domain of Aurora-A, and some of the avail-
able inhibitors of Aurora-A induce an unusually distorted confor-
mation of this domain, in which the transactivation loop [featuring
an Asp(D)-Phe(F)-Gly(G) sequence] adopts an apparently non-
physiological conformation (‘‘DFG-up’’) (Dodson et al., 2010;
Sloane et al., 2010). The goal of this study was to test the effect
of such inhibitors on N-Myc expression and stability and deter-
mine their therapeutic potential in a mouse model of MYCN-
driven neuroblastoma.
RESULTS
We showed previously that Aurora-A forms a complex with
N-Myc in MYCN-amplified neuroblastoma cells, which protects
N-Myc from proteasomal degradation in mitosis (Otto et al.,
2009). This activity was specific for Aurora-A, since neither
enhanced expression of Aurora-B nor small interfering RNA
(siRNA)-mediated depletion of Aurora-B affected N-Myc protein
levels (Figures S1A and S1B available online). Stabilization of
N-Myc does not require the catalytic activity of Aurora-A (Otto(D) IMR-32 cells were preincubatedwith 1,000 nMMLN8054 or solvent control for
indicated time points, and immunoblotted with the indicated antibodies. Exposu
(E) Quantification of five independent N-Myc stability assays performed as describ
1 for both conditions (***p < 0.0001; **p < 0.02; differences at later time points w
(F) IMR-32 cells were pretreated with 1,000 nM MLN8054 or solvent control for 2
panel shows immunoprecipitations using N-Myc antibodies or controls after the
(G) Quantitation of N-Myc stability assays. The panel shows the average (mean ±S
(F) in IMR-32 cells (**p < 0.02; *p < 0.05).
(H) IMR-32 cells were treated for 14 hr with 1,000 nM MLN8054 in the presence o
(n = 2).
See also Figure S1.et al., 2009). However, recent crystallographic work shows that
the Aurora-A-specific inhibitor MLN8054 (Manfredi et al., 2007)
induces a DFG-up conformation, in which multiple residues
have an altered position relative to ATP-bound Aurora-A, raising
the possibility that MLN8054 disrupts the Aurora-A/N-Myc com-
plex (Dodson et al., 2010; Sloane et al., 2010). This result promp-
ted us to test whether MLN8054 might affect N-Myc stability.
We therefore treated MYCN-amplified neuroblastoma IMR-32
and IMR-5 cells with increasing concentrations of MLN8054
(Manfredi et al., 2007). Treatment with MLN8054 abolished auto-
phosphorylation of Aurora-A at Thr288 (T288) and caused a
concentration-dependent decrease in N-Myc protein levels (Fig-
ure 1A). Treatment of three additional MYCN-amplified neuro-
blastoma lines also decreased N-Myc protein levels (Figures
1B and S1C). In all cell lines, the decrease in N-Myc levels was
apparent after 24 hr of treatment (Figure S1C). In four of five lines,
there was a further decrease between 24 and 48 hr (compare
Figure 1B, 48 hr, with Figure S1C, 24 hr). MLN8054 abolished
autophosphorylation of Aurora-A at T288 but had no consistent
effects on the autophosphorylation of Aurora-B and Aurora-C,
consistent with it being a specific Aurora-A inhibitor at the con-
centrations used here (Figures 1B and S1C). Furthermore,
MLN8054 did not significantly alter the expression of GSK3b
and the phosphorylation of GSK3b at Ser9 (Figures S1C and
S1G). This observation is consistent with the lack of effect of
either overexpression or siRNA-mediated depletion of Aurora-A
on GSK3b phosphorylation and argues that Aurora-A does not
affect N-Myc stability via effects on GSK3b or its upstream reg-
ulators (Figures S1D and S1E) (Faisal et al., 2011). Similarly, incu-
bation of MYCN-amplified neuroblastoma cell lines with the
clinical lead compound MLN8237, which is structurally closely
related to MLN8054, decreased N-Myc protein levels, arguing
that this is not an off-target effect of MLN8054 (Figure S1F)
(Manfredi et al., 2011).
Treatment with MLN8054 or MLN8237 had little effect on
MYCN messenger RNA (mRNA) levels and decreased levels
of N-Myc expressed from a heterologous promoter in SH-EP
neuroblastoma cells, demonstrating that both compounds
decrease N-Myc levels via a posttranscriptional mechanism
(Figures 1C, S1G, and S1H). In normal neuronal progenitors,
N-Myc is degraded in G2/M, since degradation is initiated by
phosphorylation by cyclin B/CDK1 (Sjostrom et al., 2005). Fluo-
rescence-activated cell sorting (FACS) experiments showed that
approximately 70% of IMR-32 cells accumulated in G2/M upon
treatment with MLN8054 or MLN8237 for 24 hr (Figure S1F).
Under these conditions, measurements of N-Myc stability by
blockade of new protein synthesis using cycloheximide showed
that MLN8054 accelerated the turnover of approximately 70%of24 hr as indicated, then treatedwith cycloheximide (100 mg/ml), harvested at the
res of N-Myc blots were adjusted to equalize exposure at 0 min (n = 5).
ed in (D). Data are plotted as mean ±SEM. Levels of N-Myc at 0 min were set to
ere not statistically significant).
4 hr as indicated and subsequently labeled with 35S-labeled methionine. The
indicated chase times.
EM) of three independent pulse-chase experiments performed as described in
r absence of MG132 (5 mM) and then immunoblotted for the indicated proteins
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Figure 2. Structurally Related Aurora-A Inhibitors Dissociate Aurora-A/N-Myc Complexes
(A) IMR-32 cells were treated with MLN8054 (1,000 nM, 4 hr) in the presence of MG132 (5 mM). Subsequently, cell lysates were immunoprecipitated with either
control or N-Myc antibodies and probed with the indicated antibodies. Input: cell lysate loading control. Relative amounts of Aurora-A and of Max recovered in
N-Myc immunoprecipitates are indicated below each panel (n = 4). Asterisk indicates light chain of antibody.
(B) The experiment was performed as described in (A) in the presence of the indicated concentrations of MLN8237 (n = 2).
(C) IMR-32 cells were treated with either DMSO or the indicated concentrations of MLN8237 (4 hr) in the presence of MG132. Subsequently, cell lysates were
immunoprecipitated with either control or Aurora-A antibodies. Immunoblots depict amounts of the indicated proteins (n = 4). Input: cell lysate loading control.
(D) Proximity ligation assays analyzing N-Myc/Aurora-A and N-Myc/Max complexes in SH-EP cells stably expressing N-Myc. Blue, DAPI staining of nuclei; red
dots, PCR amplification products indicating complex formation of N-Myc with Aurora-A or with Max as indicated. Scale bars indicate 10 mm. Where indicated,
MLN8237 (500 nM) or MK5108 (1,000 nM) was added for 4 hr (n = 3). SH-EP cells not expressing N-Myc serve as negative control. Lower panel showsmean +SD
of triplicate biological replicates.
(legend continued on next page)
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Aurora-A Inhibitors Target N-Myctotal N-Myc protein, whereas the remaining pool of N-Myc was
more stable (Figures 1D and 1E). Similarly, pulse-chase experi-
ments showed that about half of newly synthesized, endogenous
N-Myc protein was rapidly degraded in the presence of
MLN8054 in IMR-32 cells (Figures 1F and 1G). The same result
was obtained using MLN8237 (Figure S1I). Furthermore,
MLN8054 destabilized the ectopically expressed N-Myc protein
in SH-EP cells (Figure S1J). Finally, the effect of MLN8054 was
reverted by addition of the proteasome inhibitor, MG132 (Fig-
ure 1H). We concluded that MLN8054 and MLN8237 stimulate
degradation of N-Myc by the proteasome. The data also suggest
that MLN8054 selectively destabilizes a pool of N-Myc that is
sensitive to degradation by Fbxw7 in mitosis; this hypothesis is
tested below.
Destabilization of N-Myc might be either an indirect conse-
quence of cell-cycle arrest in G2/M due to inhibition of the cata-
lytic activity of Aurora-A or a specific effect of MLN8054 or
MLN8237 on Aurora-A/N-Myc complexes. To discern between
these possibilities, we compared the effect of different Aurora-A
inhibitors on N-Myc levels, N-Myc/Aurora-A complexes, and
cell-cycle progression. Addition of MLN8054 or MLN8237
decreased the amount of Aurora-A that coimmunoprecipitated
with N-Myc when either compound was added to IMR-32 neuro-
blastoma cells in the presence of the proteasome inhibitor
MG132 to block degradation of N-Myc (Figures 2A and 2B).
Conversely, about 1% of total N-Myc was recovered in Aurora-A
immunoprecipitates from IMR-32 cells, and incubation with
MLN8237 in the presence of MG132 reduced this amount (Fig-
ure 2C). In contrast, MLN8054 had no effect on the amount of
Max that bound to N-Myc, demonstrating that it specifically
disrupts the N-Myc/Aurora-A complex (Figure 2A). Proximity
ligation assays revealed that the Aurora-A/N-Myc complex is
present in the nucleus and in the cytosol of virtually all interphase
cells and showed that both MLN8237 and MLN8054 decreased
the amount of the complex by approximately 80%, consistent
with the results obtained in immunoprecipitation experiments
(Figure 2D; data not shown) (Gullberg et al., 2003). MLN8054
also decreased the amount of N-Myc bound to Aurora-A when
the immunopurified complex was incubated with the compound
in vitro, demonstrating that MLN8054 acts directly on the com-
plex (Figure S2A).
As expected from inhibition of the Aurora-A kinase activity,
two selective Aurora-A inhibitors with dissimilar chemical struc-
tures, MK5108 and CCT137690, also induced accumulation
of IMR-32 cells in the G2/M phase to the same extent as
MLN8054 and MLN8237 (Figure S1F) (Seki et al., 2008).
Unlike MLN8054 and MLN8237, however, neither MK5108 nor
CCT137690 nor the pan-Aurora inhibitor Hesperadin disrupted
the Aurora-A/N-Myc complex (Figures 2D–2F and S2B) (Faisal
et al., 2011; Shimomura et al., 2010). Importantly, extensive titra-
tions of MLN8054, MLN8237, and MK5108 in multiple cell lines
showed that the ability to dissociate the Aurora-A/N-Myc com-
plex correlated with the ability to decrease N-Myc levels (Fig-(E) IMR-32 cells were treated with the indicated concentrations of CCT137690 (4
described in (B).
(F) Quantitation of Aurora-A/N-Myc complexes in response to treatment with MLN
inhibitor performed as described above.
See also Figure S2.ure S2C). We concluded that destabilization of N-Myc requires
dissociation of Aurora-A/N-Myc complexes by MLN8054 or
MLN8237.
Titration of MLN8054 and MLN8237 revealed that the IC50
values for the decrease in N-Myc levels and for dissociation of
the Aurora-A/N-Myc complex are significantly higher than the
concentration required for inhibition of the autophosphorylation
of Aurora-A at T288 (Figures 2B, 2F, S2C, S3A, and S3B).
Assuming that the accessibility of the Aurora-A/N-Myc complex
is equal to that of free Aurora-A, this difference might reflect the
additional energy required to disrupt the Aurora-A/N-Myc com-
plex. Alternatively, this elevated IC50 value reflects an off-target
effect of the drug. To distinguish between these possibilities,
we expressed doxycycline-inducible alleles of either wild-type
Aurora-A or Aurora-AT217D, a mutant allele that has a reduced
affinity toward MLN8054, in MYCN-amplified SMS-KCN neuro-
blastoma cells (Sloane et al., 2010). The addition of MLN8054
suppressed colony formation of control cells and of cells ex-
pressing wild-type Aurora-A (Figure 3A). In contrast, cells that
expressed Aurora-AT217D were capable of colony formation in
the presence of MLN8054, and Aurora-A kinase remained active
under these conditions (Figures 3A and 3B). Importantly, cells
expressing Aurora-AT217D maintained elevated N-Myc levels
in the presence of MLN8054, in contrast to control cells or
cells expressing wild-type Aurora-A (Figure 3B). Furthermore,
immunoprecipitation assays revealed that the N-Myc/Aurora-
AT217D complex remained stable in the presence of MLN8054
(Figure 3C). As an additional control to demonstrate that the
ability to inhibit N-Myc expression is an on-target activity of
MLN8054, we used a small series of structurally related com-
pounds with well-characterized affinities toward Aurora-A. The
ability of these compounds to affect N-Myc expression paral-
leled their inhibition of Aurora-A, further supporting the notion
that MLN8054 and structurally related compounds regulate
N-Myc levels via dissociation of an Aurora-A/N-Myc complex
(Figure 3D).
A key ubiquitin ligase that mediates ubiquitination of N-Myc is
Fbxw7 (Welcker et al., 2004; Yada et al., 2004). Fbxw7 recog-
nizes N-Myc after sequential phosphorylation at S62 by cyclin
B/CDK1, which primes N-Myc for phosphorylation at T58 by
GSK3b (Sjostrom et al., 2005; Yeh et al., 2004). Consequently,
Fbxw7 does not recognize a mutant allele of N-Myc, which
carries alanine substitutions atboth residues (N-MycT58AS62A=
N-Mycmut) (Sjostrom et al., 2005). This mutant is neither bound
nor stabilized by Aurora-A, suggesting that Aurora-A specifically
antagonizes degradation by Fbxw7 (Otto et al., 2009). Consistent
with these observations, MLN8054 decreased levels of ectopi-
cally expressed N-Myc, but not N-Mycmut, in SH-EP neuro-
blastoma cells that do not express endogenous N-Myc
(Figure 4A). Depletion of Fbxw7 in IMR-32 cells enhanced
steady-state levels of endogenous N-Myc and abolished the
MLN8054-induced decrease in N-Myc levels, whereas depletion
of HectH9/Huwe1, another ubiquitin ligase that is involved in thehr) in the presence of MG132. N-Myc/Aurora-A complexes were analyzed as
8237, CCT137690, and MK5108. Data are shown for one experiment for each
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Figure 3. Effects of Aurora-A Inhibitors on N-Myc in Cells Expressing Wild-Type Aurora-A and Drug-Resistant Aurora-AT217D
(A) MYCN-amplified SMS-KCN cells were stably transduced with expression plasmids encoding a tetracycline-dependent transactivator. They were subse-
quently stably transduced with control vector or vector expressing hemagglutinin (HA)-tagged wild-type Aurora-A or Aurora-AT217D. Pools of cells were sub-
sequently treated with MLN8054 (500 nM) and doxycycline (1 mg/ml) as indicated. The panels show colony assays stained with crystal violet 4 days later (n = 3).
(B) Immunoblot analysis of the SMS-KCN cells described in (A) depicting expression of the indicated proteins; MLN8054 was added for 48 hr (500 nM) (n = 3).
(C) The SMS-KCN cells described in (A) were treated with MLN8054 (2,000 nM; 4 hr) in the presence of MG132 (5 mM) and doxycycline (1 mg/ml; 12 hr) as
indicated. Cell lysates were prepared and immunoprecipitated with HA antibodies. The panels show immunoblots probedwith the indicated antibodies. Levels of
N-Myc recovered in HA immunoprecipitates (relative to DMSO-treated cells) are indicated below each lane (n = 2).
(D) IMR-32 cells were incubated with the indicated series of MLN8054 derivatives (1,000 nM; 24 hr). The upper panels show immunoblots of cell lysates probed
with the indicated antibodies (n = 3). IC50 data of these compounds from in vitro assays of Aurora-A kinase are shown at the bottom.
See also Figure S3.
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Figure 4. Role of Fbxw7 in MLN8054-Induced Degradation of N-Myc
(A) SH-EP cells were stably transduced with retroviruses expressing either N-Myc (WT) or N-MycT58AS62A (mut) then incubated with MLN8054 (1,000 nM; 48 hr)
or solvent control as shown. The panels show immunoblots of cell lysates probed with the indicated antibodies (n = 3).
(B) Immunoblots of IMR-32 cells that were transfected with indicated siRNAs. Cells were incubated with MLN8054 or solvent control for 24 hr and analyzed as in
panel A (n = 3). Ratios of N-Myc to vinculin are indicated below the panel.
(C) IMR-32 were transfected with siRNA targeting FBXW7 or control siRNA. Then 24 hr before harvesting, cells were treated with MLN8054 (1,000 nM) or DMSO
as control. CHX was added for the indicated times. Exposures of N-Myc blots were adjusted to equalize exposure at 0 min (n = 3).
(D) Quantification of three independent stability experiments performed as described for (C). Levels of N-Myc at 0 min were set to 1 for all conditions. Values are
shown as mean ±SEM (*p < 0.02 relative to siFbxw7-treated cells).
(E) SH-EP cells engineered to stably express wild-type N-Myc were incubated with MLN8054 (1,000 nM) for the times shown. Immunoblots depict expression of
the indicated proteins (n = 2).
(F) IMR-32 were incubated with MLN8054 (1,000 nM) for the indicated times before lysates were prepared and blotted as before.
(G) IMR-5 neuroblastoma cells were incubated with the indicated drugs for 18 hr. The panels show immunoblots of cell lysates probed with the indicated
antibodies. Amounts of N-Myc relative to Cdk2 are indicated below each lane (n = 2).
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Figure 5. Role of N-Myc in Cellular Responses of MYCN-Amplified Neuroblastoma Cells to MLN8054
(A) The panel on the left shows crystal violet-stained culture dishes of SMS-KCN cells grown in the presence of MLN8054 (250 nM) or solvent control for 4 days.
The graph in the middle documents proliferation of SMS-KCN cells under the same conditions. Error bars indicate SD of triplicate biological replicates.
Immunoblots on the right depict levels of the indicated proteins 48 hr after addition of MLN8054.
(B) FACS analysis showing cell cycle phases of SMS-KCN cells in response to MLN8054 (250 nM; 48 hr) (left). The data were combined with the growth curve
shown in (A) to calculate the length of each cell-cycle phase (right). Error bars indicate SD of triplicate biological replicates.
(C) The graph shows levels of CDKN1A mRNA relative to b2-microglobulin and RPS14 as control determined by quantitative RT-PCR. The indicated cell lines
were incubated with MLN8054 (1,000 nM) or DMSO for 48 hr before RNA was prepared. Error bars indicate SD of triplicate technical replicates from one of two
experiments with identical results.
(D) LAN-1 cells were stably transduced with lentiviruses expressing either wild-type N-Myc or N-Mycmut and the experiment performed as described in (C). Error
bars indicate SD of triplicate technical replicates.
(legend continued on next page)
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Aurora-A Inhibitors Target N-Mycubiquitin-mediated degradation of N-Myc, had no significant
effect (Figure 4B). Importantly, depletion of Fbxw7 stabilized
N-Myc and reverted the enhanced turnover of N-Myc in the pres-
ence of MLN8054 (Figures 4C and 4D). Note that because the
depletion of HectH9/Huwe1 is not complete, we cannot rule
out a contribution of residual HectH9/Huwe1 to N-Myc turnover
in response to MLN80454.
The addition of MLN8054 for 24 hr destabilized about 50%–
70% of total N-Myc protein, suggesting that a specific pool of
N-Myc is sensitive to MLN8054; this corresponds to the fraction
of cells that are in G2/M upon inhibitor treatment. Furthermore,
overall levels of N-Myc decreased progressively over 24–48 hr
in response toMLN8054, suggesting thatMLN8054might desta-
bilize N-Myc when cells have progressed to G2 and M phase
(Figures 4E and 4F). Degradation of N-Myc by Fbxw7 is initiated
by the mitotic kinase, cyclin B/CDK1 (Sjostrom et al., 2005). As a
result, depletion of Aurora-A strongly affects N-Myc levels in
cells synchronized in mitosis by the addition of nocodazole;
degradation is further enhanced by inhibition of PI3-kinase,
which activates GSK3b to phosphorylate T58 of N-Myc (Otto
et al., 2009). Similarly, addition of MLN8054 enhanced N-Myc
turnover in response to PI3-kinase inhibition by LY294002 in
nocodazole-treated cells (Figure 4G). The same result was ob-
tained using the dual PI3-kinase/mTOR inhibitor BEZ235 (not
shown). The data strongly suggest that Aurora-A protects
N-Myc from Fbxw7-mediated degradation during mitosis and
that the slow kinetics of decrease is due to the requirement for
mitotic phosphorylation of N-Myc.
Incubation with MLN8054 suppressed colony formation and
inhibited proliferation of all MYCN-amplified neuroblastoma
cell lines that we tested (Figures 5A and S4A). IC50 values for
suppression of proliferation of MYCN-amplified neuroblastoma
lines range between 250 and 700 nM, consistent with the possi-
bility that downregulation of N-Myc contributes to growth inhibi-
tion (Shang et al., 2009). FACSscan experiments showed that the
predominant response of MYCN-amplified SMS-KCN cells to
treatment with MLN8054 was a delay in progression through
both the G1 and the G2 phase of the cell cycle, similar to the
response elicited by small hairpin RNA-mediated depletion of
Aurora-A (Figure 5B) (Otto et al., 2009). Prolonged incubation
with MLN8054 also induced varying degrees of apoptosis in
MYCN-amplified neuroblastoma cell lines (Figure 5B; data not
shown). While the delay in progression through G2 is likely to
reflect catalytic functions of Aurora-A in mitotic entry (see
above), we speculated that the delay in progression through
the G1 phase may depend on degradation of N-Myc. Consistent
with previous observations that N-Myc represses expression of
the cell-cycle inhibitor CDKN1A (encoding p21Cip1) (Herold
et al., 2002), incubation with MLN8054 induced a significant(E) Immunoblots documenting expression of N-Myc or N-Mycmut in LAN-1 cells ex
expressed N-Myc is not completely degraded in response to MLN8054.
(F) SMS-KCN cells were infected with either control viruses (empty) or retroviruses
with uninfected cells such that 20% of cells expressed GFP at the start of the expe
the absence or presence of MLN8054 (100 nM). Error bars represent SD of trip
estimated: control cells: DMSO: 26 hr; MLN8054: 36 hr; N-Myc- and N-Mycmut-e
(G) Immunoblots documenting expression of the indicated proteins at the end of th
have selected for elevated levels of N-Myc.
See also Figure S4.increase in expression of CDKN1A in four out of five MYCN-
amplified cell lines tested (Figure 5C). Induction of CDKN1A in
response to MLN8054 was independent of p53 status, since it
also occurred in LAN-1 cells that do not express detectable
p53 and, to a lesser degree, in Kelly cells (Figure 5C) and since
it was not blocked by expression of a dominant-negative allele
of p53 (Figures S4B and S4C). Ectopic expression of N-Myc
or N-Mycmut in MYCN-amplified cells attenuated induction of
CDKN1A, arguing that elimination ofMYCN is required for induc-
tion ofCDKN1A expression (Figure 5D). Note that the ectopically
expressed N-Myc protein was not completely degraded in the
presence of MLN8054 in these experiments (Figure 5E). Identical
results were obtained in SHEP cells ectopically expressing or N-
Myc or N-Mycmut (Figure 4A). Importantly, ectopic expression of
N-Myc and N-Mycmut provided a moderate proliferative advan-
tage to MYCN-amplified cells in the absence of MLN8054 but
a much stronger advantage in the presence of MLN8054
(SMS-KCN cells: Figure 5F; IMR-5 cells: data not shown). This
correlated with their ability to suppress MLN8054-induced
expression of p21Cip1 (Figure 5G). We concluded that elimination
of N-Myc is required for the complete arrest of cell proliferation
and for the induction of p21Cip1 expression by MLN8054 in
cultured MYCN-amplified neuroblastoma cells.
Murine Aurora-A binds to the human N-Myc protein (Fig-
ure S5A), allowing us to use the TH-MYCN mouse model of
aggressive neuroblastoma, in which high-level expression of
MYCN is driven in neural crest by a tyrosine hydroxylase (TH)
promoter, to evaluate the therapeutic efficacy of MLN8054 and
MLN8237 in an in vivo setting (Weiss et al., 1997). Mice with large
established tumors were initially treated with daily oral adminis-
tration of 40 mg/kg MLN8054. After 3 days of treatment, immu-
noblots revealed a large decrease in N-Myc protein in four out
of six tumors and a modest decrease in two out of six tumors
in comparison to vehicle-treated tumors (Figure 6A). Treatment
with 30 mg/kg MLN8237 inducedmore rapid decreases in tumor
volume (p = 0.022; Figure S5B), and downregulation of N-Myc
was observed in eight out of eight tumors after 24 hr (p =
0.0023; Figure S5C). Downregulation of N-Myc occurred post-
translationally, since levels of human and mouse MYCN mRNA
were unaffected by MLN8054 or MLN8237 (Figure S5D). To
test whether MLN8054 affects the amount of N-Myc bound
to its target sites in vivo, we performed chromatin immunopre-
cipitation (ChIP) experiments from three vehicle- and three
MLN8054-treated mice. These experiments revealed that
N-Myc specifically bound to the E-box of the Apex promoter, a
well-characterized target gene of N-Myc, and that treatment
with MLN8054 strongly reduced binding to this site (Figure 6B).
Identical results were obtained for the Myc-binding sites
localized in the Ncl1 and Slc25a19 genes (not shown). Toposed toMLN8054 (1,000 nM; 48 hr) or solvent control. Note that the ectopically
expressing N-Myc or N-Mycmut together with a GFPmarker. Cells were mixed
riment. The graph shows the percentage of GFP-positive cells during culture in
licate biological samples. From the data, the following doubling times can be
xpressing cells: DMSO: 25 hr; MLN8054: 32 hr (n = 2).
e experiment shown in (F). Note that cells growing in the presence of MLN8054
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Figure 6. Effects of MLN8054 on N-Myc
Function in TH-MYCN Neuroblastoma Mice
(A) Tumor-bearing TH-MYCN mice were treated
for 3 days with 40 mg/kg MLN8054 or vehicle. The
panels on the left show immunoblots of lysates
of neuroblastomas probed with the indicated
antibodies. Spleen tissue is included as negative
control for N-Myc antibody. The panel on the right
shows a quantification of the immunoblot (data
are plotted as mean +SEM).
(B) Results of ChIP assays using N-Myc or control
antibodies at a genomic region surrounding the E
box of the Apex gene or a negative control region
as indicated. Error bars indicate SD of triplicate
technical replicates.
(C) RNA was isolated from four MLN8054-treated
and from four vehicle-treated neuroblastomas
and subjected to microarray analysis. The panels
show expression of well-characterized gene sets
of MYC-regulated genes and their response to
MLN8054 treatment.
(D) The graphs show Kaplan-Meier diagrams of
human patients stratified by the expression levels
of the gene sets shown in (C). Graphs and p values
are shown for overall survival.
See also Figure S5.
Cancer Cell
Aurora-A Inhibitors Target N-Mycdetermine how the observed decreases in N-Myc affect the tran-
scriptional functions of N-Myc, we used microarrays to compare
gene expression profiles of four MLN8054-treated tumors
against four vehicle-treated tumors. Gene set enrichment anal-
ysis (GSEA) showed strong modulation of expression of multiple
Myc target gene sets in response to MLN8054, demonstrating
that MLN8054 interferes with N-Myc-dependent transcription
in vivo (Figure 6C) (Subramanian et al., 2005). The prognostic84 Cancer Cell 24, 75–89, July 8, 2013 ª2013 Elsevier Inc.relevance of gene sets regulated by
MLN8054 was investigated in a cohort
of 476 primary neuroblastomas repre-
senting the entire spectrum of the disease
(Oberthuer et al., 2010). Prognostic clas-
sifiers based on MLN8054-regulated
gene sets were generated in a training
set comprising approximately half of
the total cohort, and their classification
performance was evaluated in the re-
maining test set. Importantly, we ob-
served that gene sets regulated by
MLN8054 in the mouse model were
strongly associated with both overall
(Figure 6D) and event-free survival (Fig-
ure S5E) of neuroblastoma patients. We
concluded that treatment with MLN8054
interferes with critical oncogenic func-
tions of N-Myc in vivo.
GSEA analysis also provided evidence
that MLN8054 reduced expression of
genes that are characteristic of plu-
ripotent stem cells, suggesting that
MLN8054 limits the self-renewal capacity
of neuroblastoma cells (Figure S5F)(Wong et al., 2008). In support of this contention, treatment
withMLN8054 abolished the ability of IMR-5 cells to growas neu-
rospheres in culture (Figure S5G). MLN8054 also downregulated
N-Myc, abolished clonogenic growth, and induced expression of
neurofilament protein LmRNA (NEFL), amarker of differentiation,
in a primary neurosphere culture derived froma patient with bone
marrow metastasis, supporting the notion that the MLN8054
results extend to human disease (Figures S5H and S5I).
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response rates around 50% for both compounds (Figures 7A,
7B, S6A, and S6B; four out of nine complete responses with
MLN8054 and five out of eight complete responses with
MLN8237). Histological analysis of tumors recovered from
mice after 1 day (MLN8237) or 3 days (MLN8054) of treatment
revealed highly significant increases in mitotic activity, with
neuronal differentiation consistent with partial maturation of
tumors, and inflammatory infiltrates (Figures 7C and S6C). There
were also prominent sheets of foamy histiocytes, indicative of
inflammation. Immunohistological analysis showed that both
drugs increased the percentage of cells staining positively for
phosphoH3, indicative of an accumulation in G2 and mitosis
(Figures 7D, S6C; quantification of staining is in Figure S6D for
MLN8054 and S6E for MLN8237). In addition, there was a
decrease in N-Myc staining intensity, supporting the immunoblot
data. Consistent with the reduction of clonogenic growth
observed in vitro, treatment with MLN8054 increased the num-
ber of cells staining positively for the senescence marker
H3K9me and decreased expression of Bmi1, which is critical
for the self-renewal of neuronal progenitor cells (Bruggeman
et al., 2005). Neither MLN8054 nor MLN8237 induced a sig-
nificant increase in apoptotic cells. Finally, treatment with
MLN8054 induced infiltration of immune cells, including macro-
phages (stained with Mac2) and T-lymphocytes (Figure 7D; data
not shown).
Exposure of tumor-bearing mice to 40 mg/kg MLN8054 re-
sulted in rapid tumor regression. However, this high dose was
not tolerated well in long-term experiments, which complicated
the interpretation of survival studies (not shown). A lower split
dose of 15 mg/kg twice daily was well tolerated, significantly
extended survival (p = 0.0016), and decreased N-Myc levels
in vivo (Figures 7E and S6F). Treatment with MLN8237 was
well tolerated and resulted in a more pronounced extension
of survival (Figure 7F; p = 0.0004). In similar trials, neither
MK5108 nor CCT137690 had significant effects on survival,
tumor growth, or N-Myc levels (data not shown). However,
mass spectrometry and immunoblots of Aurora-AT288P revealed
that effective intratumoral levels of either compound were vari-
able even at high oral doses, precluding a definitive assessment
of their efficacy. Taken together, our data show that both
MLN8054 and MNL8237 effectively destabilize the N-Myc pro-
tein, cause a blockade of N-Myc function, and achieve signifi-
cant therapeutic benefit in this in vivo model of neuroblastoma.
DISCUSSION
The N-Myc protein differs from the founding member of the
family, c-Myc, in that degradation of N-Myc is initiated via phos-
phorylation by cyclin B/CDK1 and therefore tightly linked to
mitosis (Sjostrom et al., 2005). The mitotic degradation of
N-Myc is thought to allow cell-cycle exit and differentiation of
neuroblasts. In human neuroblastoma cells, Aurora-A forms a
complex with the N-Myc protein that stabilizes N-Myc in mitosis,
thereby maintaining neuroblastoma cells in a proliferative state
(Otto et al., 2009). We show here that MLN8237 and MLN8054
disrupt the Aurora-A/N-Myc complex. Phosphorylation of
N-Myc by cyclin B/CDK1 initiates ubiquitination of N-Myc by
Fbxw7 (Welcker et al., 2004; Yada et al., 2004). Consistently,we found that Fbxw7 is required for degradation of N-Myc in
response to disruption of the Aurora-A/N-Myc complex. The
exact mechanism by which complex formation of N-Myc with
Aurora-A prevents degradation of N-Myc is currently unknown.
Notably, approximately 1% of N-Myc was recovered in Aurora-A
immunoprecipitates, arguing that Aurora-A does not act by
sterically blocking the access of Fbxw7 to N-Myc. Rather, we
suggest that Aurora-A recruits a stabilizing activity; possible can-
didates are a S62 phosphatase such as PP2A or a deubiquitinat-
ing enzyme such as Usp28 (Horn et al., 2007; Popov et al., 2007)
(Figure 8).
In response to MLN8054 or MLN8273, N-Myc levels
decreased progressively over a 24–48 hr time period, which
cannot be explained by the short half-life of N-Myc. Proximity-
ligation assays showed that the Aurora-A/N-Myc complex is
detectable in virtually all cells. We propose, therefore, that the
slow kinetics of N-Myc degradation reflects the need for cyclin
B/CDK1 to phosphorylate N-Myc in mitosis. Since inhibition of
the catalytic activity of Aurora-A delays entry into mitosis (Seki
et al., 2008), we suggest that purely allosteric inhibitors of
Aurora-A, which disrupt the Aurora-A/N-Myc complex but do
not inhibit the catalytic activity of Aurora-A, may have a more
rapid impact on N-Myc levels.
Treatment with MLN8054 broadly inhibits N-Myc dependent
transcription in vivo. Genes that are downregulated in response
to MLN8054 are prognostically significant in human neuroblas-
toma. They include genes that mediate oncogenic functions of
Myc and that in turn have been proposed to be therapeutic
targets for Myc-dependent tumors, such as ODC1 and CDK4
(Miliani de Marval et al., 2004; Nilsson et al., 2005). In addition,
treatment of neuroblastomas with MLN8054 or MLN8237 in-
duces senescence and differentiation as well as infiltration of
immune cells, phenotypes that are thought to mediate tumor
regression in response to inhibition of Myc in regulatable mouse
tumor models (Rakhra et al., 2010; Sodir et al., 2011). Consistent
with induction of senescence, MLN8054 diminishes expression
of Bmi1, which is a critical regulator of stem cell functions, and
represses a stem cell-specific gene expression program. We
suggest that these effects contribute to the ability of MLN8054
and MLN8237 to prolong survival in the N-Myc-dependent
mouse model of neuroblastoma. This remains to be formally
proven, since MK5103 and CCT137690, which did not disrupt
the Aurora-A/N-Myc complex in culture and did not affect sur-
vival in the TH-MYCN model, did not consistently accumulate
to high enough concentrations in the tumor tissue to allow defin-
itive conclusions about their therapeutic efficacy. Similarly, it re-
mains possible that the decrease in N-Myc levels observed
in vivo occurs via a mechanism that is different from Fbxw7-
mediated degradation.
MLN8237 is currently in phase 2 clinical evaluations for child-
hood neuroblastoma (NCT01154816). The plasma concentration
of the drug in these trials is around 2 mM, which is sufficient to
disrupt the Aurora-A/N-Myc complex (Matulonis et al., 2012).
The identification of N-Myc as a critical target of this class of
Aurora-A inhibitors suggests rational strategies for further ther-
apy development. For example, structural considerations sug-
gest that it is possible to optimize inhibitors to more strongly
distort the Aurora-A structure and thereby more effectively
disrupt the Aurora-A/N-Myc complex. As described above,Cancer Cell 24, 75–89, July 8, 2013 ª2013 Elsevier Inc. 85
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Figure 8. Model to Explain Our Findings
In normal neuroblasts, degradation of N-Myc is initiated by phosphorylation at
S62 of N-Myc by cyclin B/CDK1; this primes N-Myc for phosphorylation by
GSK3 at T58. The pool of doubly phosphorylated N-Myc in cells in G2/M is
recognized by Fbxw7. The association of N-Myc with Aurora-A in neuroblas-
toma cells blocks degradation by Fbxw7 and allows N-Myc to persist into the
subsequent cell cycle. MLN8237 and MLN8054 disrupt the association,
thereby restoring a more physiological pattern of N-Myc degradation.
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Aurora-A Inhibitors Target N-Mycallosteric drugs can be envisaged that disrupt the Aurora-A/
N-Myc complex while retaining the ability of Aurora-A to promote
entry into mitosis, potentially leading to more rapid phosphoryla-
tion and degradation of N-Myc. Furthermore, degradation of
N-Myc in response to MLN8054 is enhanced by inhibition of
PI3-kinase, which promotes phosphorylation of N-Myc at T58
and has therapeutic efficacy in preclinical models of neuro-
blastoma (Chanthery et al., 2012). Similarly, small molecules
targeting Brd4 allow inhibition of transcription from the MYCN
promoter, so combinations with either drug may further
decrease N-Myc protein levels below critical thresholds (Del-
more et al., 2011). Our findings therefore also offer strategies
to develop future combination therapies for MYCN-amplified
neuroblastoma and potentially other N-Myc-dependent tumors.
EXPERIMENTAL PROCEDURES
Tissue Culture
Neuroblastoma cell lines were cultured in RPMI 1640 supplemented with
10% heat-inactivated fetal bovine serum. The primary neuroblastoma sphere
culture was established from a highly infiltrated bone marrow aspirate of a
neuroblastoma patient. Informed consent was obtained from the patient
according to a research proposal approved by the institutional review board
of the Medical Faculty of the University of Heidelberg. Cells were seeded inFigure 7. In Vivo Trials of MLN8054 and MLN8237 in TH-MYCN Neurob
(A and B) Representative day 0 and 7 MRI sections of mice treated with vehicle or
tumor circumference.
(C) Hematoxylin and eosin staining of sections of tumors frommice treatedwith ve
right). Black arrows (top row) indicate neuronal differentiation with the presence of
cells. Orange arrows (bottom row) show a multivacuolated histiocytic componen
(D) Immunohistochemistry of tumors treated as (A), using indicated antibodies. S
(E) Kaplan-Meier plot documenting survival of mice treated twice daily with 15 m
(F) Kaplan-Meier plot documenting survival of mice treated with 30 mg/kg MLN8
See also Figure S6.neurosphere medium (Neurobasal A, Gibco Invitrogen) supplemented with
B27 serum substitute (Gibco Invitrogen), 20 ng/ml bFGF (Promokine),
20 ng/ml bFGF (Promokine), and 2 mg/ml heparin (Sigma-Aldrich) and were
cultured at 37C, 5% CO2. For colony assays, cells were fixed with 70%
ethanol and stained with crystal violet. FACS analysis was performed using
propidium iodide staining of ethanol-fixed cells via a FACSCantoII(BD) flow
cytometer.
In Vivo Experiments
All experimental protocols were monitored and approved by The Institute of
Cancer Research Animal Welfare and Ethical Review Body, in compliance
with guidelines specified by the UK Home Office Animals (Scientific Proce-
dures) Act 1986 and the United Kingdom National Cancer Research Institute
guidelines for the welfare of animals in cancer research (Workman et al.,
2010). Transgenic TH-MYCN mice were genotyped to detect the presence
of human MYCN transgene (Weiss et al., 1997). After weaning, animals were
palpated for intra-abdominal tumors twice weekly. Mice with palpable tumors
(40–80 days old) were treated with the indicated doses of MLN8054,
MLN8237, or vehicle. For the MLN8054 and MLN8237 experiments shown in
Figures 7E and 7F, mice were treated with indicated dose twice a day for
5 days, and then treatment was stopped for 2 days before the schedule
resumed, for 2 weeks. Drugs were administered via oral gavage. Mice were
allowed access to food and water ad libitum.
In Vivo Imaging and Histopathology
MRI was performed on a 7T horizontal bore microimaging system (Bruker
Instruments) using a 3 cm birdcage coil. Anatomical T2-weighted coronal
images were acquired from 20 contiguous 1-mm-thick slices through the
mouse abdomen, from which tumor volumes were determined using segmen-
tation from regions of interest drawn on each tumor-containing slice. At the
end of trials, tumors were dissected, divided into six approximately equal
pieces, and fixed with 4% paraformaldehyde or snap frozen in liquid nitrogen.
Tissue sections were stained with hematoxylin and eosin or specific anti-
bodies. Immunohistochemistry was performed using standard methods by
Histopathox Ltd. Briefly, 5 mm sections were stained with antibodies, including
heat-induced epitope retrieval using citrate buffer (pH 6) or EDTA buffer, and
scored by a consultant histopathologist.
Immunological Methods
Tumor or spleen tissue were homogenized using T-PER buffer (Thermo
Scientific) containing 13 complete proteinase inhibitor tablet (Roche) per
10 ml buffer and a cocktail of phosphatase inhibitors (Santa Cruz). Protein
concentration was measured by bicinchoninic acid assay. Protein (30 mg)
was denatured in lithium dodecyl sulfate sample buffer (Invitrogen), separated
on precast 4%–12%Bis-Tris gels (Invitrogen), and transferred to nitrocellulose
membranes. Immunoblots were recorded electronically on a Fujifilm LAS-4000
scanner. Tomeasure N-Myc stability, IMR-32 and SH-EP cells were pulsed for
30 min with 35S-labeled methionine and chased for 0, 15, 30, or 60 min; alter-
natively, new protein synthesis was blocked by addition of 100 mg/ml cyclo-
heximide. Cells were lysed with NP40 buffer, adjusted to equal incorporation,
and N-Myc was immunoprecipitated using DYNAbeads. Immunoprecipita-
tions lacking a primary antibody or with control antibodies were used as con-
trols for specificity. ChIP experiments were performed as described elsewhere
(Bouchard et al., 2001). Antibodies are listed in Supplemental Experimental
Procedures.lastoma Mice
40 mg/kg MLN8054 (A) or 30 mg/kg MLN8237 (B). Dashed white lines indicate
hicle or 40mg/kgMLN8054 at day 3 (high-magnification views are shownon the
variablymaturing ganglion-like cells. Green arrows (middle row) indicatemitotic
t around tumors. Scale bars represent 50 mm (left and middle) or 10 mm (right).
cale bar represents 50 mm.
g/kg MLN8054 versus vehicle.
237 versus vehicle.
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Total RNA was reverse transcribed into complementary DNA (cDNA) using
random hexanucleotide primers and M-MLV reverse transcriptase. Quantita-
tive RT-PCR was performed in triplicates with cDNA corresponding to 40 ng
total RNA using Absolute QPCR SYBR Green mix (ABgene) on the Mx3000P
system (Stratagene) at a 60C annealing temperature. Relative expression
was calculated according to the DDCt relative quantification method using
the average expression of RPS14 and B2M as calibrator. Primers are listed
in Supplemental Experimental Procedures.
In Situ Proximity Ligation Assay
Duolink in situ proximity ligation assay (PLA; Olink Bioscience) was performed
on fixed adherent cells according to the manufacturer’s instructions. Briefly,
SH-EP neuroblastomas cells expressing N-Myc were fixed in 4% paraformal-
dehyde for 30min, permeabilizedwith 0.2%Triton X-100, and blockedwith the
manufacturer’s blocking agent for 1 hr followed by incubation with paired pri-
mary antibodies, N-Myc (Calbiochem) with Aurora-A (Cell Signaling) or Max
(Cell Signaling), for 1 hr. PLA detection was performed as recommended by
the manufacturer. Images were taken and analyzed using the InCell Analyzer
1000 (Plan 203 objective).
Additional experimental procedures can be found in Supplemental
Information.ACCESSION NUMBERS
All microarray data have been deposited in the ArrayExpress database (http://
www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-179.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.05.005.
ACKNOWLEDGMENTS
We thank Hermann Schindelin and Richard Bayliss for their advice on
analyzing the MLN8054/Aurora-A interaction. This study was supported by
grants from the Federal Ministry of Education and Research (‘‘NGFN plus’’;
to M.E., H.E.D., and O.W.), the Christopher’s Smile Project (grant
CSM001X), SPARKS (grant 09RMH01), The Neuroblastoma Society (grant
NES003X), and the Medical Research Council (MRC; grant NC3R-
G1000121/94513 to L.C.). We also acknowledge The Institute of Cancer
Research CR-UK and EPSRC Cancer Imaging Centre, in association with
the MRC and Department of Health (England) grant C1060/A10334 (to S.R.),
NHS funding to the NIHR Biomedical Research Centre, and The Wellcome
Trust (grant 091763Z/10/Z; to S.R.). We thank Florence Raynaud, Amin Mirza,
Albert Hallsworth, Zai Ahmad, and Karen Barker for guidance with in vivo
studies and members of the Eilers and Chesler laboratories for their critical
reading of and comments on the manuscript.
Received: May 17, 2012
Revised: April 21, 2013
Accepted: May 8, 2013
Published: June 20, 2013
REFERENCES
Beltran, H., Rickman, D.S., Park, K., Chae, S.S., Sboner, A., MacDonald, T.Y.,
Wang, Y., Sheikh, K.L., Terry, S., Tagawa, S.T., et al. (2011). Molecular charac-
terization of neuroendocrine prostate cancer and identification of new drug
targets. Cancer Discov. 1, 487–495.
Bouchard, C., Dittrich, O., Kiermaier, A., Dohmann, K., Menkel, A., Eilers, M.,
and Lu¨scher, B. (2001). Regulation of cyclin D2 gene expression by the Myc/
Max/Mad network: Myc-dependent TRRAP recruitment and histone acetyla-
tion at the cyclin D2 promoter. Genes Dev. 15, 2042–2047.88 Cancer Cell 24, 75–89, July 8, 2013 ª2013 Elsevier Inc.Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E., and Bishop, J.M.
(1984). Amplification of N-myc in untreated human neuroblastomas correlates
with advanced disease stage. Science 224, 1121–1124.
Bruggeman, S.W., Valk-Lingbeek, M.E., van der Stoop, P.P., Jacobs, J.J.,
Kieboom, K., Tanger, E., Hulsman, D., Leung, C., Arsenijevic, Y., Marino, S.,
and van Lohuizen, M. (2005). Ink4a and Arf differentially affect cell proliferation
and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 19,
1438–1443.
Chanthery, Y.H., Gustafson, W.C., Itsara, M., Persson, A., Hackett, C.S.,
Grimmer, M., Charron, E., Yakovenko, S., Kim, G., Matthay, K.K., and
Weiss, W.A. (2012). Paracrine signaling through MYCN enhances tumor-
vascular interactions in neuroblastoma. Science translational medicine 4,
115ra113.
Chen, X., Xu, H., Yuan, P., Fang, F., Huss,M., Vega, V.B.,Wong, E., Orlov, Y.L.,
Zhang, W., Jiang, J., et al. (2008). Integration of external signaling pathways
with the core transcriptional network in embryonic stem cells. Cell 133,
1106–1117.
Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M.,
Kastritis, E., Gilpatrick, T., Paranal, R.M., Qi, J., et al. (2011). BET bromodo-
main inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917.
Dodson, C.A., Kosmopoulou, M., Richards, M.W., Atrash, B., Bavetsias, V.,
Blagg, J., and Bayliss, R. (2010). Crystal structure of an Aurora-A mutant
that mimics Aurora-B bound to MLN8054: insights into selectivity and drug
design. Biochem. J. 427, 19–28.
Faisal, A., Vaughan, L., Bavetsias, V., Sun, C., Atrash, B., Avery, S., Jamin, Y.,
Robinson, S.P., Workman, P., Blagg, J., et al. (2011). The aurora kinase inhib-
itor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuro-
blastoma in vivo. Mol. Cancer Ther. 10, 2115–2123.
Gullberg, M., Fredriksson, S., Taussig, M., Jarvius, J., Gustafsdottir, S., and
Landegren, U. (2003). A sense of closeness: protein detection by proximity
ligation. Curr. Opin. Biotechnol. 14, 82–86.
Hatton, B.A., Knoepfler, P.S., Kenney, A.M., Rowitch, D.H., de Albora´n, I.M.,
Olson, J.M., and Eisenman, R.N. (2006). N-myc is an essential downstream
effector of Shh signaling during both normal and neoplastic cerebellar growth.
Cancer Res. 66, 8655–8661.
Herold, S., Wanzel, M., Beuger, V., Frohme, C., Beul, D., Hillukkala, T.,
Syvaoja, J., Saluz, H.P., Haenel, F., and Eilers, M. (2002). Negative regulation
of the mammalian UV response by Myc through association with Miz-1. Mol.
Cell 10, 509–521.
Horn, V., The´lu, J., Garcia, A., Albige`s-Rizo, C., Block, M.R., and Viallet, J.
(2007). Functional interaction of Aurora-A and PP2A during mitosis. Mol.
Biol. Cell 18, 1233–1241.
Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C.,
Finkelstein, D., Qu, C., Pounds, S., Ellison, D.W., et al. (2012). A mouse model
of the most aggressive subgroup of human medulloblastoma. Cancer Cell 21,
168–180.
Kim, Y.H., Girard, L., Giacomini, C.P., Wang, P., Hernandez-Boussard, T.,
Tibshirani, R., Minna, J.D., and Pollack, J.R. (2006). Combined microarray
analysis of small cell lung cancer reveals altered apoptotic balance and distinct
expression signatures of MYC family gene amplification. Oncogene 25,
130–138.
Manfredi, M.G., Ecsedy, J.A., Meetze, K.A., Balani, S.K., Burenkova, O., Chen,
W., Galvin, K.M., Hoar, K.M., Huck, J.J., LeRoy, P.J., et al. (2007). Antitumor
activity of MLN8054, an orally active small-molecule inhibitor of Aurora A
kinase. Proc. Natl. Acad. Sci. USA 104, 4106–4111.
Manfredi, M.G., Ecsedy, J.A., Chakravarty, A., Silverman, L., Zhang, M., Hoar,
K.M., Stroud, S.G., Chen, W., Shinde, V., Huck, J.J., et al. (2011).
Characterization of Alisertib (MLN8237), an investigational small-molecule in-
hibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin.
Cancer Res. 17, 7614–7624.
Marumoto, T., Zhang, D., and Saya, H. (2005). Aurora-A - a guardian of poles.
Nat. Rev. Cancer 5, 42–50.
Matulonis, U.A., Sharma, S., Ghamande, S., Gordon, M.S., Del Prete, S.A.,
Ray-Coquard, I., Kutarska, E., Liu, H., Fingert, H., Zhou, X., et al. (2012).
Cancer Cell
Aurora-A Inhibitors Target N-MycPhase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhib-
itor, in patients with platinum-resistant or -refractory epithelial ovarian, fallo-
pian tube, or primary peritoneal carcinoma. Gynecol. Oncol. 127, 63–69.
Miliani de Marval, P.L., Macias, E., Rounbehler, R., Sicinski, P., Kiyokawa, H.,
Johnson, D.G., Conti, C.J., and Rodriguez-Puebla, M.L. (2004). Lack of cyclin-
dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues.
Mol. Cell. Biol. 24, 7538–7547.
Nilsson, J.A., Keller, U.B., Baudino, T.A., Yang, C., Norton, S., Old, J.A.,
Nilsson, L.M., Neale, G., Kramer, D.L., Porter, C.W., and Cleveland, J.L.
(2005). Targeting ornithine decarboxylase in Myc-induced lymphomagenesis
prevents tumor formation. Cancer Cell 7, 433–444.
Oberthuer, A., Hero, B., Berthold, F., Juraeva, D., Faldum, A., Kahlert, Y.,
Asgharzadeh, S., Seeger, R., Scaruffi, P., Tonini, G.P., et al. (2010).
Prognostic impact of gene expression-based classification for neuroblastoma.
J. Clin. Oncol. 28, 3506–3515.
Otto, T., Horn, S., Brockmann, M., Eilers, U., Schu¨ttrumpf, L., Popov, N.,
Kenney, A.M., Schulte, J.H., Beijersbergen, R., Christiansen, H., et al.
(2009). Stabilization of N-Myc is a critical function of Aurora A in human neuro-
blastoma. Cancer Cell 15, 67–78.
Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards,
R., Moll, R., Elledge, S.J., and Eilers, M. (2007). The ubiquitin-specific protease
USP28 is required for MYC stability. Nat. Cell Biol. 9, 765–774.
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A.,
Fan, A.C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010). CD4(+) T cells
contribute to the remodeling of the microenvironment required for sustained
tumor regression upon oncogene inactivation. Cancer Cell 18, 485–498.
Seki, A., Coppinger, J.A., Jang, C.Y., Yates, J.R., and Fang, G. (2008). Bora
and the kinase Aurora a cooperatively activate the kinase Plk1 and control
mitotic entry. Science 320, 1655–1658.
Shang, X., Burlingame, S.M., Okcu, M.F., Ge, N., Russell, H.V., Egler, R.A.,
David, R.D., Vasudevan, S.A., Yang, J., and Nuchtern, J.G. (2009). Aurora A
is a negative prognostic factor and a new therapeutic target in human neuro-
blastoma. Mol. Cancer Ther. 8, 2461–2469.
Shimomura, T., Hasako, S., Nakatsuru, Y., Mita, T., Ichikawa, K., Kodera, T.,
Sakai, T., Nambu, T., Miyamoto, M., Takahashi, I., et al. (2010). MK-5108, a
highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and
in combination with docetaxel. Mol. Cancer Ther. 9, 157–166.
Sjostrom, S.K., Finn, G., Hahn, W.C., Rowitch, D.H., and Kenney, A.M. (2005).
The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and
turnover in neural precursors. Dev. Cell 9, 327–338.
Sloane, D.A., Trikic, M.Z., Chu, M.L., Lamers, M.B., Mason, C.S., Mueller, I.,
Savory, W.J., Williams, D.H., and Eyers, P.A. (2010). Drug-resistant aurora Amutants for cellular target validation of the small molecule kinase inhibitors
MLN8054 and MLN8237. ACS Chem. Biol. 5, 563–576.
Sodir, N.M., Swigart, L.B., Karnezis, A.N., Hanahan, D., Evan, G.I., and
Soucek, L. (2011). Endogenous Myc maintains the tumor microenvironment.
Genes Dev. 25, 907–916.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and
Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. USA 102, 15545–15550.
Valentijn, L.J., Koster, J., Haneveld, F., Aissa, R.A., van Sluis, P., Broekmans,
M.E., Molenaar, J.J., van Nes, J., and Versteeg, R. (2012). Functional MYCN
signature predicts outcome of neuroblastoma irrespective of MYCN amplifica-
tion. Proc. Natl. Acad. Sci. USA 109, 19190–19195.
Weiss, W.A., Aldape, K., Mohapatra, G., Feuerstein, B.G., and Bishop, J.M.
(1997). Targeted expression of MYCN causes neuroblastoma in transgenic
mice. EMBO J. 16, 2985–2995.
Welcker, M., Orian, A., Jin, J., Grim, J.E., Harper, J.W., Eisenman, R.N., and
Clurman, B.E. (2004). The Fbw7 tumor suppressor regulates glycogen syn-
thase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc.
Natl. Acad. Sci. USA 101, 9085–9090.
Wenzel, A., Cziepluch, C., Hamann, U., Schu¨rmann, J., and Schwab, M.
(1991). The N-Myc oncoprotein is associated in vivo with the phosphoprotein
Max(p20/22) in human neuroblastoma cells. EMBO J. 10, 3703–3712.
Wong, D.J., Liu, H., Ridky, T.W., Cassarino, D., Segal, E., and Chang, H.Y.
(2008). Module map of stem cell genes guides creation of epithelial cancer
stem cells. Cell Stem Cell 2, 333–344.
Workman, P., Aboagye, E.O., Balkwill, F., Balmain, A., Bruder, G., Chaplin,
D.J., Double, J.A., Everitt, J., Farningham, D.A., Glennie, M.J., et al.;
Committee of the National Cancer Research Institute. (2010). Guidelines for
the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555–
1577.
Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki,
H., Ishida, N., Okumura, F., Nakayama, K., and Nakayama, K.I. (2004).
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box
protein Fbw7. EMBO J. 23, 2116–2125.
Yeh, E., Cunningham,M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn,
W.C., Stukenberg, P.T., Shenolikar, S., Uchida, T., et al. (2004). A signalling
pathway controlling c-Myc degradation that impacts oncogenic transforma-
tion of human cells. Nat. Cell Biol. 6, 308–318.Cancer Cell 24, 75–89, July 8, 2013 ª2013 Elsevier Inc. 89
